Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Rochelle

Pain Medicine Hammond, LA Medical Doctor

NPI 1689998601 CMS profile 1340637

15770 Paul Vega MD Dr, Suite 206, Hammond, LA 70403

Open in the dashboard

General payments

$844

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jared Rochelle of Hammond, LA is reported in the CMS Open Payments database as having received $844 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53 3
2022 General $24 1
2020 General $85 5
2019 General $683 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Rochelle
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jared Rochelle were reported at $53. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Jared Rochelle Pain Medicine median Middle half National median
2019 $683 $409 $115–$1,311 $163
2020 $85 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $24 $335 $103–$1,149 $149
2023 $0 $376 $114–$1,228 $160
2024 $0 $387 $115–$1,173 $164
2025 $53 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $127 7 payments
  2. UCB, Inc. $125 10 payments
  3. Stryker Corporation $101 3 payments
  4. Boston Scientific Corporation $63 2 payments
  5. Zyla Life Sciences $45 3 payments
  6. TerSera Therapeutics LLC $44 2 payments
  7. Promius Pharma LLC $37 2 payments
  8. Vertical Pharmaceuticals, LLC $35 2 payments
  9. SI-BONE, Inc. $30 2 payments
  10. Acorda Therapeutics, Inc $28 2 payments
  11. Other $208 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $816 45 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28 2 payments
Products named General payments · program years 2019–2025
  1. Fycompa $127 7 payments
  2. Vimpat $108 9 payments
  3. ES2 $48 1 payment
  4. CLINICAL TRIAL PRODUCT $47 1 payment
  5. SPRIX $45 3 payments
  6. PRIALT $44 2 payments
  7. ZEMBRACE SYMTOUCH $37 2 payments
  8. LORZONE $35 2 payments
  9. IFUSE IMPLANT $30 2 payments
  10. INBRIJA $28 2 payments
  11. Other $309 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,707

Median for Interventional Pain Management: 1,220

Drug cost

$31,646

Median for Interventional Pain Management: $39,344

Branded share of claims

27.5%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 270 $5,034
Movantik Naloxegol Oxalate Brand 11 $4,603
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 162 $4,303
Lidocaine Generic 36 $3,851
Gabapentin Generic 277 $3,237
Baclofen Generic 166 $1,970
Diclofenac Sodium Generic 116 $1,612
Methocarbamol Generic 137 $1,376
Duloxetine Hcl Generic 58 $1,321
Tramadol Hcl Generic 128 $827

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$46,259

Medicare's payments for the services billed

Medicare patients

172

Average age 72

Services billed

681

97 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 40%
Chronic kidney disease 32%
Depression 30%
Heart failure 25%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record